Department of Experimental Medicine, Lleida University-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), 25198, Lleida, Spain.
Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Service of Endocrinology, University Hospital Dr. Peset, 46017, Valencia, Spain.
Sci Rep. 2019 Nov 5;9(1):16033. doi: 10.1038/s41598-019-52263-w.
Metformin is one of the treatments used for PCOS pathology decreasing body weight, plasma androgen, FSH and glucose levels. Unfortunately, there is little known about metformin's effects on lipid metabolism, a crucial process in PCOS pathology. We have employed a lipidomic approach to explore alterations in the plasma lipid profile of patients with PCOS following metformin treatment. The aim is to offer new insights about the effect of metformin in PCOS patients. Plasma samples were obtained from 27 subjects prior to and following 12 weeks of metformin treatment. A detailed biochemical characterization and lipidomic profile was performed. Metformin reduces BMI, HOMA-IR, FSH and androstenedione and increases DHEA-S but no changes were found in glucose levels after treatment. Multivariate statistics revealed a specific lipidomic signature due to the effect of 12 weeks of metformin treatment in PCOS patients. This signature includes changes in sphingolipid metabolism suggesting a crosstalk between these lipid species and the androgenic metabolism and a decrease in oxidized lipids reinforcing that metformin treatment improves oxidative stress status. Our study confirms the specific effect of metformin in lipid metabolism on women with PCOS after 12 weeks of treatment.
二甲双胍是多囊卵巢综合征病理治疗的方法之一，可降低体重、血浆雄激素、FSH 和血糖水平。不幸的是，人们对二甲双胍对脂代谢的影响知之甚少，而脂代谢是多囊卵巢综合征病理的一个关键过程。我们采用脂质组学方法来研究二甲双胍治疗后多囊卵巢综合征患者的血浆脂质谱变化。目的是提供关于二甲双胍在多囊卵巢综合征患者中作用的新见解。从 27 名患者中获得治疗前和治疗 12 周后的血浆样本。进行了详细的生化特征和脂质组学分析。二甲双胍降低 BMI、HOMA-IR、FSH 和雄烯二酮，增加 DHEA-S，但治疗后血糖水平没有变化。多变量统计显示，由于 12 周的二甲双胍治疗对多囊卵巢综合征患者的影响，出现了特定的脂质组学特征。该特征包括鞘脂代谢的变化，表明这些脂质种类与雄激素代谢之间存在相互作用，以及氧化脂质的减少，这表明二甲双胍治疗可改善氧化应激状态。我们的研究证实了二甲双胍在治疗 12 周后对多囊卵巢综合征女性脂代谢的特定作用。
